Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lupus drug enters first human safety tests

NCT ID NCT06335979

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This is an early-stage study to check the safety and how the body processes a new drug called PIT565 for people with active lupus (SLE). It will involve about 54 participants who haven't responded well to standard treatments. The main goal is to find a safe dose and see how the drug behaves in the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Novartis Investigative Site

    WITHDRAWN

    Sofia, 1612, Bulgaria

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100191, China

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100730, China

  • Novartis Investigative Site

    RECRUITING

    Berlin, 10117, Germany

  • Novartis Investigative Site

    RECRUITING

    Mainz, 55131, Germany

  • Novartis Investigative Site

    RECRUITING

    Budapest, H-1083, Hungary

  • Novartis Investigative Site

    RECRUITING

    Szeged, 6725, Hungary

  • Novartis Investigative Site

    RECRUITING

    Leiden, South Holland, 2333 CL, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28034, Spain

  • Novartis Investigative Site

    RECRUITING

    Bern, 3010, Switzerland

  • Novartis Investigative Site

    WITHDRAWN

    Sankt Gallen, 9007, Switzerland

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)